Active, not recruitingPHASE2, PHASE3NCT04713982

Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

Studying Huntington disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vanderbilt University Medical Center
Principal Investigator
Amy E Brown, MD
Vanderbilt University Medical Center
Intervention
Deutetrabenazine(drug)
Enrollment
30 enrolled
Eligibility
18 years · All sexes
Timeline
20212026

Study locations (1)

Collaborators

Teva Branded Pharmaceutical Products R&D, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04713982 on ClinicalTrials.gov

Other trials for Huntington disease

Additional recruiting or active studies for the same condition.

See all trials for Huntington disease

← Back to all trials